Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P43234
UPID:
CATO_HUMAN
Alternative names:
-
Alternative UPACC:
P43234
Background:
Cathepsin O, encoded by the gene with the accession number P43234, is a proteolytic enzyme that plays a crucial role in cellular protein degradation and turnover. This enzyme is part of the cathepsin family, known for their significant contributions to the lysosomal degradation pathway, a critical process for cellular homeostasis and recycling of cellular components.
Therapeutic significance:
Understanding the role of Cathepsin O could open doors to potential therapeutic strategies. Its involvement in protein degradation and turnover suggests its potential implications in diseases where these processes are dysregulated. Targeting Cathepsin O could offer novel approaches in treating such conditions.